Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Docetaxel and Capecitabine as 1st Line Therapy for Patients With Locally Advanced or Metastatic Gastric Cancer

NCT00142038 is registered in ClinicalTrials.gov with Charite University, Berlin, Germany as lead sponsor.

NCT NCT00142038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00142038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Docetaxel and Capecitabine as 1st Line Therapy for Patients With Locally Advanced or Metastatic Gastric Cancer
Lead sponsor
Charite University, Berlin, Germany
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2004
Completion date
December 31, 2007
Enrollment
80
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastasis, stomach neoplasm